

Contents

1 Radiation Oncology Advances: An Introduction	1
<i>Søren M. Bentzen, Paul M. Harari, Wolfgang A. Tomé, and Minesh P. Mehta</i>	
Advances in Imaging and Theragnostic Radiation Oncology	1
Advances in Molecular Biology and Targeted Therapies	2
Advances in Treatment Delivery and Planning	3
Clinical Advances	4
References	4
Section I. Advances in Imaging and Biologically-Based Treatment Planning	
2 Advanced Image-Guided External Beam Radiotherapy	7
<i>Thomas Rockwell Mackie and Wolfgang Tomé</i>	
Introduction	7
Image Guidance for Defining Target Volumes	9
Image Guidance at the Time of Delivery	13
Optical Guidance	14
Optical Tracking Systems	15
Optical Tracking in Fractionated Stereotactic Radiotherapy, Intracranial, and Head and Neck IMRT	16
Optically Guided Ultrasound	18
In-Room CT Guidance	20
Image Guidance and Organ Motion	27
Image Guidance for Follow-Up Imaging and Retreatments	29
Summary	31
References	32

3 Dose Painting and Theragnostic Imaging: Towards the Prescription, Planning and Delivery of Biologically Targeted Dose Distributions in External Beam Radiation Oncology.....	40
<i>Søren M. Bentzen</i>	
Radiation Theragnostics	40
From Anatomical to Biological Targeting in Radiation Therapy.....	41
From Target Selection and Delineation to 4D Dose Prescription	42
The Case for Nonuniform Theragnostic Dose Distributions.....	43
Precision Requirements	46
Targeting Hypoxia Using EBRT: Are We Ready for Dose Painting by Numbers?.....	47
Hypoxia as a Cause of Clinical Failure of Radiation Therapy	47
Hypoxia Imaging	49
Spatiotemporal Stability of the PET Hypoxia Map	52
Dose Painting by Numbers	55
Dose Delivery and Expected Change in Outcome.....	56
Conclusion	56
References.....	57
4 Molecular and Functional Imaging in Radiation Oncology.....	62
<i>Robert Jeraj and M. Elizabeth Meyerand</i>	
Introduction.....	62
Molecular and Functional Imaging Modalities	63
Positron Emission Tomography.....	63
Single Photon Emission Tomography.....	64
Dynamic Contrast Enhanced Computer Tomography (DCE-CT)	64
Dynamic Contrast Enhanced Magnetic Resonance Imaging(D CE-MRI).....	64
Magnetic Resonance Spectroscopy.....	65
Optical Imaging	65
Comparison Between Different Imaging Modalities.....	65
Molecular and Functional Imaging Targets.....	66
Cellular Metabolism.....	67
Cellular Proliferation	71
Cellular Death	72
Cellular Regulation	73
Tumor Microenvironment.....	76
Future	79
References.....	81

5 Prognostic and Predictive Markers in Radiation Therapy: Focus on Prostate Cancer	95
<i>Mark A. Ritter</i>	
Introduction.....	95
The Need for Biomarkers of Radiation Response in Prostate Cancer	95
Optimal Biomarkers and Patient Cohort Characteristics.....	96
Evaluation of Candidate Markers	97
Biological Rationale.....	97
Biomarker Frequency.....	100
Biomarker Assessment Methods	100
Immunohistochemistry	101
Clinical Correlative Data in Prostate Cancer.....	102
Markers of Cell Cycle Control, DNA Repair and Apoptosis.....	103
Proliferation	103
Hypoxia.....	104
Limitations of Existing Studies	104
Future Studies and Directions.....	105
Large Prospective Clinical Trials.....	105
Biomarker-Based Adaptive Therapy.....	106
Conclusion	107
References.....	107
 Section II. Advances in Molecular Biology and Targeted Therapies	
6 Overview of Cancer Molecular Radiobiology	115
<i>Jann N. Sarkaria and Robert G. Bristow</i>	
Introduction.....	115
Interaction of Radiation with Living Cells.....	115
Cellular Response to Ionizing Radiation.....	116
Cell Cycle Arrest	116
DNA Repair	118
Apoptosis	119
Cell Survival Signaling.....	120
Ras Signaling	120
Receptor Tyrosine Kinases.....	121
mTOR Signaling.....	121
Targeting Housekeeping Proteins	122
HSP90 Inhibitors	123
HDAC Inhibitors	124
Proteasome Inhibitors	126
Conclusion	127
References.....	128

7 Clinical Application of EGFR Inhibitors in Head and Neck Squamous Cell Cancer	132
<i>Igor Atsaturov, Roger B. Cohen, and Paul M. Harari</i>	
Introduction.....	132
EGFR Biology	133
Anti-EGFR Monoclonal Antibodies.....	135
Radiation Plus Cetuximab For Locoregionally Advanced HNSCC	135
Cetuximab, Cisplatin, and Radiation in Locoregionally Advanced HNSCC	137
Cetuximab ± Chemotherapy in Recurrent and/or Metastatic HNSCC	138
Cetuximab with Chemotherapy in the First-Line Treatment of Patients with Recurrent and/or Metastatic HNSCC.....	139
EGFR Tyrosine Kinase Inhibitors (TKIs)	140
TKI Monotherapy in HNSCC	141
TKIs in Combination with Radiation Therapy	141
TKIs with Dual Specificity	142
Patient Selection.....	142
Conclusions.....	143
References.....	144
8 Advancement of Antiangiogenic and Vascular Disrupting Agents Combined with Radiation	150
<i>Deborah Citrin and Kevin Camphausen</i>	
Introduction.....	150
Tumor Vasculature	150
Targeting the Tumor Vasculature.....	152
Antiangiogenic Agents	152
Vascular Disrupting Agents	155
Combining Antiangiogenic and Vascular Disrupting Agents with Radiation.....	157
Antiangiogenic Agents and Radiation in the Laboratory	157
Angiogenesis Inhibitors and Radiation in the Clinic	159
Vascular Disrupting Agents and Radiation in the Laboratory	160
Vascular Disrupting Agents with Radiation in the Clinic.....	161
Future Directions	162
Conclusion	163
References.....	164
9 Overcoming Therapeutic Resistance in Malignant Gliomas: Current Practices and Future Directions	169
<i>Arnab Chakravarti and Kamalakannan Palanichamy</i>	
Introduction.....	169
Signal Transduction Pathways Involved in Treatment Resistance	169
Angiogenesis Pathways	171

Conventional Chemotherapeutic Agents in Malignant Gliomas	173
Biotherapeutic Strategies	178
Antiepidermal Growth Factor Receptor (EGFR) Strategies	178
mTor Pathway Inhibition: CCI-779	180
Antiangiogenic Strategies	181
Summary	182
References	182
 Section III. Advances in Treatment Delivery and Planning	
10 Advances in Intensity-Modulated Radiotherapy Delivery	189
<i>John D. Fenwick, Stephen W. Riley, and Alison J.D. Scott</i>	
Introduction	189
Background	189
Fixed-Field IMRT	190
Direct Aperture Optimisation and Jaws-Only	
Linear Accelerator IMRT	195
Tomotherapy	195
Axial Tomotherapy	196
Helical Tomotherapy	197
Future Developments	202
CyberKnife	204
Summary	205
References	206
 11 Image-Based Modeling of Normal Tissue Complication Probability	
for Radiation Therapy	211
<i>Joseph O. Deasy and Issam El Naqa</i>	
Introduction	211
NTCP Models: Tools or Toys?	212
Why Image-Based NTCP Analysis?	214
Tissue Dose–Response Classification	215
The Concepts of “Serial” and “Parallel” Tissue Dose–Response	215
Local vs. Global Organ Injuries	217
NTCP Models	218
The Generalized Equivalent Uniform Dose Equation	219
Basic Mathematical Features of Common NTCP Functions	221
Cluster Models	223
A Data-Mining/Data-Driven Approach to NTCP Modeling	223
Selection of Relevant Input Variables	227
Selection of Model Functional Form	228
Selection of Model Order	229
Model Order Based on Information Theory	229
Model Order Based on Cross-validation Methods	231
Model Variable Stability	231

Model Parameter Fitting	231
Image-Based Factors and Radiosensitivity Predictors.....	232
Some Critical NTCP Endpoints.....	233
Late Rectal Toxicity Due to External Beam Prostate Cancer Treatment	233
Radiation Pneumonitis Due to Thoracic Irradiation for Lung Cancer.....	234
Xerostomia Due to Head and Neck Cancer Treatment.....	236
Drawbacks to Treatment Planning Based on Dose–Volume Limits	239
Uncertainties in NTCP Models	240
Incorporating Fractionation Sensitivity	241
Summary	244
References.....	244
12 Optimization of Radiotherapy Using Biological Parameters	253
<i>Yusung Kim and Wolfgang Tomé</i>	
Introduction.....	253
The Need for Optimization Based on Biological Parameters	255
Radiobiological Models.....	256
Biological Optimization.....	260
Subvolume-Based Radiobiological Models.....	260
Impact of Diagnostic Accuracy on Biological Optimization	266
Functional Imaging in Oncology	266
Theranostic Imaging in Risk-Adaptive Radiotherapy.....	266
The Impact of Imaging Sensitivity on Risk-Adaptive Radiotherapy	267
Clinical Parameters Necessary for Biological Optimization	268
Summary	270
References.....	271
Section IV. Clinical Advances	
13 Combined Chemoradiotherapy Advances.....	277
<i>Gordon Wong and Minesh P. Mehta</i>	
Introduction.....	277
Head and Neck Cancers.....	278
Nonsmall Cell Lung Carcinoma	284
Cervical Carcinoma	288
Esophageal Carcinoma	290
Rectal Adenocarcinoma.....	292
Anal Squamous Cell Carcinoma.....	294
Muscle Invasive Bladder Cancer	295
Conclusion	296
References.....	296

14 Cytoprotection for Radiation-Associated Normal Tissue Injury	302
<i>Jingfang Mao, Oluwatoyosi A. Fatunase, and Lawrence B. Marks</i>	
Biologic Rationale of Cytoprotectors	302
Assessment of Amifostine in Patients with Head and Neck Cancer.....	304
Assessment of Amifostine in Patients with Thoracic Tumors	304
Lung Injury	304
Esophageal Injury	307
Assessment of Amifostine in Patients with Pelvic Tumors.....	307
Assessment of Amifostine in Patients with Tumors at Other Sites.....	307
Impact of Amifostine on Tumor Control and Survival	309
Amifostine-Related Toxicity.....	309
Administration of Amifostine.....	309
Other Cytoprotectors.....	316
Conclusion	318
References.....	318
Index	323